The results of a study on the rat model of NAFLD treated with an inhibitor of JNK showed that the expression levels of ATG3 and ATG5 were decreased, insulin resistance was reduced, and NAFLD was improved [164]. The gene discussed is ATG5; the disease is metabolic dysfunction-associated steatotic liver disease.